Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Greenheck

Nurse Practitioner, Family New Orleans, LA Nurse Practitioner

NPI 1396871158 CMS profile 153930

1415 Tulane Ave, Tw-4, New Orleans, LA 70112

Open in the dashboard

General payments

$14,650

218 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Greenheck of New Orleans, LA is reported in the CMS Open Payments database as having received $14,650 across 218 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,506 106
2024 General $5,313 42
2023 General $1,193 48
2022 General $454 17
2021 General $185 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Greenheck
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jennifer Greenheck were reported at $7,506. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jennifer Greenheck Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $185 $124 $35–$379 $132
2022 $454 $141 $44–$430 $149
2023 $1,193 $154 $49–$476 $160
2024 $5,313 $165 $51–$504 $164
2025 $7,506 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $10,466 53 payments
  2. AstraZeneca Pharmaceuticals LP $1,302 36 payments
  3. GlaxoSmithKline, LLC. $745 47 payments
  4. Regeneron Healthcare Solutions, Inc. $675 22 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $298 10 payments
  6. Verona Pharma, Inc. $251 8 payments
  7. Mylan Specialty L.P. $125 6 payments
  8. Baxter Healthcare $119 5 payments
  9. Insmed, Inc. $98 5 payments
  10. Amgen Inc. $60 3 payments
  11. Other $511 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $6,648 2 payments
  2. Food and Beverage $6,020 209 payments
  3. Travel and Lodging $1,982 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,109 38 payments
  2. FASENRA $783 13 payments
  3. DUPIXENT Immunology And Inflammation $457 13 payments
  4. TRELEGY ELLIPTA $439 33 payments
  5. BREZTRI $419 14 payments
  6. NUCALA $306 14 payments
  7. Ohtuvayre $251 8 payments
  8. AIRSUPRA $248 6 payments
  9. TEZSPIRE $220 7 payments
  10. DUPIXENT Inflammation And Immunology $218 9 payments
  11. Other $1,124 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,315

Median for Nurse Practitioner: 389

Drug cost

$524,812

Median for Nurse Practitioner: $21,885

Branded share of claims

79.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 213 $154,164
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 190 $140,241
Dupixent Pen Dupilumab Brand 15 $57,199
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 104 $54,721
Spiriva Respimat Tiotropium Bromide Brand 72 $51,624
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 33 $18,924
Ozempic Semaglutide Brand 13 $11,968
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 14 $11,012
Serevent Diskus Salmeterol Xinafoate Brand 24 $10,145
Albuterol Sulfate Hfa Albuterol Sulfate Brand 307 $7,896

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$8,264

Medicare's payments for the services billed

Medicare patients

63

Average age 73

Services billed

124

38 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 49%
COPD 37%
Ischemic heart disease 29%
Diabetes 24%
Cancer 22%
Heart failure 21%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $296
  • Regeneron Healthcare Solutions, Inc. $108
$405 15 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $96
  • Amgen Inc. $25
$121 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $58
$58 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $51
$51 — —
YUPELRI
  • Mylan Specialty L.P. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record